Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Bicara Therapeutics Inc. (BCAX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB) and Bicara Therapeutics Inc. (BCAX) with bullish sentiments.

Meet Samuel – Your Personal Investing Prophet

• Start a conversation with TipRanks’ trusted, data-backed investment intelligence
• Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

Biogen (BIIB)

In a report released today, Myles Minter from William Blair maintained a Buy rating on Biogen. The company’s shares closed last Friday at $193.46.

According to TipRanks.com, Minter is a 5-star analyst with an average return of 32.3% and a 56.5% success rate. Minter covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, CAMP4 Therapeutics Corporation, and Neumora Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $218.76 average price target, implying a 14.8% upside from current levels. In a report issued on May 15, Evercore ISI also initiated coverage with a Buy rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

Bicara Therapeutics Inc. (BCAX)

JonesTrading analyst Boris Peaker maintained a Buy rating on Bicara Therapeutics Inc. today and set a price target of $30.00. The company’s shares closed last Friday at $21.73.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 21.2% and a 45.3% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Adlai Nortye Ltd. Sponsored ADR, Monopar Therapeutics Inc, and ArriVent BioPharma, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Bicara Therapeutics Inc. with a $30.55 average price target, implying a 46.6% upside from current levels. In a report issued on May 10, Guggenheim also initiated coverage with a Buy rating on the stock with a $42.00 price target.

Read More on BIIB:

Disclaimer & DisclosureReport an Issue

• Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints
• Biogen Earnings Call Signals Confident, Investment-Heavy Transition
• Immunic appoints Michael Bonney as chair
• Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250
• Biogen: Hold Rating Reiterated as Pipeline Concerns Offset Leqembi Growth; $196 Price Target Maintained